United Therapeutics Co. (UTHR) Rating Reiterated by Jefferies Group LLC
United Therapeutics Co. (NASDAQ:UTHR)‘s stock had its “underperform” rating reiterated by research analysts at Jefferies Group LLC in a research report issued on Friday. They currently have a $116.00 price target on the biotechnology company’s stock. Jefferies Group LLC’s price target would suggest a potential downside of 18.03% from the company’s current price.
UTHR has been the subject of several other reports. Zacks Investment Research raised United Therapeutics from a “hold” rating to a “buy” rating and set a $159.00 price objective for the company in a research note on Tuesday, December 27th. Ladenburg Thalmann Financial Services downgraded United Therapeutics from a “buy” rating to a “neutral” rating and set a $145.00 price objective for the company. in a research note on Thursday, February 23rd. Wedbush reissued an “outperform” rating and issued a $229.00 price objective on shares of United Therapeutics in a research note on Wednesday, February 8th. Leerink Swann increased their price objective on United Therapeutics from $127.00 to $148.00 and gave the stock a “market perform” rating in a research note on Thursday, February 23rd. Finally, Standpoint Research downgraded United Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 19th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company. United Therapeutics currently has a consensus rating of “Hold” and an average target price of $138.31.
United Therapeutics (NASDAQ:UTHR) opened at 141.51 on Friday. The stock has a market cap of $6.36 billion, a PE ratio of 9.28 and a beta of 1.42. The firm has a 50-day moving average price of $155.60 and a 200-day moving average price of $136.69. United Therapeutics has a 12-month low of $97.52 and a 12-month high of $169.89.
United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 22nd. The biotechnology company reported $4.12 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.61 by $0.51. United Therapeutics had a return on equity of 41.78% and a net margin of 44.40%. The business earned $409 million during the quarter, compared to analyst estimates of $415.51 million. During the same quarter last year, the company posted $3.80 EPS. United Therapeutics’s revenue for the quarter was up 1.0% on a year-over-year basis. Analysts forecast that United Therapeutics will post $14.13 EPS for the current fiscal year.
Your IP Address:
In other news, Director Christopher Patusky sold 5,000 shares of the firm’s stock in a transaction dated Thursday, January 12th. The stock was sold at an average price of $141.99, for a total transaction of $709,950.00. Following the completion of the sale, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $709,950. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 1,211 shares of the firm’s stock in a transaction dated Thursday, December 29th. The stock was sold at an average price of $143.63, for a total value of $173,935.93. Following the sale, the chief executive officer now directly owns 1,351 shares of the company’s stock, valued at $194,044.13. The disclosure for this sale can be found here. Insiders have sold a total of 15,859 shares of company stock valued at $2,302,181 over the last ninety days. Company insiders own 7.50% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Ladenburg Thalmann Financial Services Inc. increased its stake in United Therapeutics by 11.3% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 717 shares of the biotechnology company’s stock worth $104,000 after buying an additional 73 shares during the period. Focused Wealth Management Inc purchased a new stake in United Therapeutics during the fourth quarter worth $115,000. Daiwa Securities Group Inc. increased its stake in United Therapeutics by 9.5% in the third quarter. Daiwa Securities Group Inc. now owns 1,150 shares of the biotechnology company’s stock worth $136,000 after buying an additional 100 shares during the period. BancorpSouth Inc purchased a new stake in United Therapeutics during the third quarter worth $224,000. Finally, Zweig DiMenna Associates LLC purchased a new stake in United Therapeutics during the third quarter worth $224,000.
United Therapeutics Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Co. and related companies with MarketBeat.com's FREE daily email newsletter.